SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCSeptember 26, 2026

Incidental thymic radiation dose was independently associated with metastasis and death in 1107 patients with NSCLC

Radiotherapy planning for non-small cell lung cancer treats the heart, the lungs, the oesophagus and the spinal cord as organs at risk. The thymus is not on that list, and a thoracic field may pass through it. A multicohort analysis published in Annals of Oncology reports that the dose the thymus receives incidentally, as a by-product of treating the tumour, was independently associated with higher risks of metastasis and death in 1107 patients, and that patients whose thymic function was still intact when treatment began appeared to be at particularly greater risk.
Share

In brief

  • Across 1107 patients with NSCLC in three cohorts, thymic radiation exposure was independently associated with higher risks of metastasis and death.
  • Each 1-Gy increase in mean thymic dose was associated with an increased distant metastasis risk of 1.57% to 4.21% after adjustment for confounders.
  • Adjusted hazard ratios were 1.29 in RTOG-0617 (P = 0.0028), 1.33 in HARVARD-CRT (P = 0.011) and 1.95 in HARVARD-DURVA (P = 0.007).
  • Patients with preserved thymic function before radiotherapy appeared to be at particularly greater risk. No association emerged in patients whose thymic function was already impaired.
  • Imaging a year after treatment showed dose-dependent declines in thymic health, with lower circulating lymphocyte counts alongside them, and an exploratory feasibility study suggested thymic sparing can be achieved without compromising tumour coverage or cardiopulmonary constraints.

Study at a glance

  • Cohorts: three, each with its own estimate: the phase III RTOG-0617 trial (n = 460), HARVARD-CRT (n = 422) and HARVARD-DURVA (n = 225)
  • Population: 1107 patients with non-small cell lung cancer
  • Treatment: HARVARD-CRT, chemoradiotherapy alone; HARVARD-DURVA, chemoradiotherapy with consolidation immunotherapy
  • Exposure measured: mean thymic dose, with thymic function scored by a deep learning system reading thymic radiographic characteristics as a proxy
  • Reported association: higher risks of metastasis and death, independent of confounders
  • Distant metastasis: adjusted HR 1.29 to 1.95 per 1 Gy of mean thymic dose, across the three cohorts
  • Thymic health subgroup: preserved thymic function appeared to carry particularly greater risk; no association emerged in impaired thymic function
  • At one year: dose-dependent decline in thymic health, with lower circulating lymphocyte counts
  • Not reported: the abstract gives no hazard ratios for the association with death, no lymphocyte count figures, and no proposed dose constraint for the thymus

A 1-Gy increase in mean thymic dose carried adjusted hazard ratios of 1.29 to 1.95 for distant metastasis

Each cohort was given its own estimate, and each returned the same direction of effect once confounders were adjusted for: 1.29 in the 460 patients of RTOG-0617 (P = 0.0028), 1.33 in the 422 patients of HARVARD-CRT (P = 0.011), and 1.95 in the 225 patients of HARVARD-DURVA (P = 0.007).

The authors put the increase in distant metastasis risk per additional gray at 1.57% to 4.21%. The conclusion they draw covers death as well as metastasis, although the abstract attaches the per-cohort hazard ratios to the metastasis endpoint alone. The largest of the three estimates came from the smallest cohort, the 225 patients given consolidation immunotherapy after chemoradiotherapy, which is the setting where reduced immune competence would be expected to matter most, although the analysis does not test that. RTOG-0617 supplies the randomised data in the set, and thymic dose in all three cohorts is an exposure that was observed rather than one that was assigned.

No association emerged in patients whose thymic function was already impaired

Stratification by thymic health before radiotherapy put the risk on the other side of the split: among patients entering treatment with a preserved thymus, the authors report that the risk appeared to be particularly greater as thymic dose rose.

Thymic function was not measured directly here. A deep learning system scored thymic radiographic characteristics on imaging and that score stood in for function, which is what allows the question to be asked at all in cohorts assembled for other purposes. It also means the stratification inherits the uncertainty of the proxy, since patients classified as impaired may include some in whom the radiographic appearance and the underlying immune function diverge. What the split does offer is a result pointing the way the hypothesis predicts, with the association appearing where there was function left to lose.

Thymic health declined with dose at one year, and lymphocyte counts were lower alongside it

Both readings are reported from the one-year follow-up, and the authors go no further than calling them consistent with a possible biological link between thymic irradiation and loss of immune competence.

Lymphopenia after chemoradiotherapy for lung cancer has been described for years and has been reported to be associated with worse outcomes, usually attributed to circulating lymphocytes irradiated in the blood pool and to marrow dose in the vertebrae and ribs. What this analysis adds is a named organ carrying a dose that a planning system can calculate. The design cannot separate thymic injury from the other routes by which thoracic radiotherapy depletes lymphocytes, and the abstract does not claim that it can.

“These findings raise awareness toward considering the thymus as an organ of interest in RT and suggest that thymus-sparing strategies may help preserve immune health and improve patient outcomes.”Prudente et al., Annals of Oncology (2026)

A feasibility test suggested thymic sparing is achievable without compromising tumour coverage

The authors label this component exploratory, and it is the one part of the analysis that varies the planning instead of observing an exposure: radiotherapy planning was reoptimised for thymic sparing, and the reoptimised plans were judged against tumour coverage and the cardiopulmonary constraints.

How many plans were reoptimised, and how much thymic dose came off them, are not set out in the abstract. The question a planner asks next is what the thymus would be traded against, since the mediastinum is crowded with structures that already carry named constraints.

The standing limit on the finding is its design. Two of the three cohorts are real-world, and the third is a trial that randomised patients to radiation dose levels rather than to thymic sparing. Consistency across three cohorts is more than any single series could offer, and it is still consistency among datasets that share the same weakness. What the authors propose is that the thymus be considered an organ of interest, which is a narrower claim than a dose constraint, and it is testable in a prospective plan comparison of the kind the feasibility work sketches.

Sources

  1. Annals of Oncology. Thymic radiation is associated with worse outcomes in patients with NSCLC (2026-08-25). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Biagio Ricciuti.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
ILCS 2026
Resectable NSCLCImmunotherapies

Latest options in early-stage NSCLC: novel IO approaches for improved outcomes

S. Patel
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Prof. Martin Reck
Nov 04 2026
SPONSORED EXPERT TALK
Resectable NSCLCImmunotherapies

MDT-BRIDGE in Resectable and Borderline Resectable NSCLC

Prof. Martin Reck presents and discusses the phase 2 MDT-BRIDGE trial in resectable and borderline resectable non-small cell lung cancer in this on-demand expert talk.

M. Reck
Dr. Jacob Sands
Nov 04 2026
SPONSORED INTERVIEW
SCLCImmunotherapies

New Therapy Options in SCLC and AE Management

Dr. Jacob Sands discusses new treatment options in small cell lung cancer and the management of their adverse events in this on-demand expert interview.

J. Sands
Oct252026
ESMO 2026 SYMPOSIUM
SCLCImmunotherapies

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.

M. ReckS. PetersG. MountziosN. Reguart
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
ILCS 2025
Immunotherapies

The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC

} 28 min

A. Filippi
Sep 26 2025
ILCS 2025
Immunotherapies

Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes

} 36 min

P. Forde
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nov 16 2026
RESEARCH
Immunotherapies

Lenvatinib plus pembrolizumab gave a median PFS of 22.1 months in pretreated thymic carcinoma and B3 thymoma

J. RemonN. GirardN. Reguart
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Nikolaj Frost
Oct 31 2026
RESEARCH
Resectable NSCLCImmunotherapies

KEYNOTE-867 tested pembrolizumab with SBRT in unresected stage I or II NSCLC

N. Frost
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Charles Rudin
Oct 30 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab gave an mOS of 13.6 months against 8.4 with chemotherapy in SCLC at extended DeLLphi-304 follow-up

C. RudinG. Mountzios
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2

T. CasconeP. Forde
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 27 2026
RESEARCH
SCLCImmunotherapies

Tarlatamab added to durvalumab maintenance extended OS in extensive-stage SCLC

J. SandsM. PérolA. Dingemans
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 23 2026
RESEARCH
SCLCImmunotherapies

KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC

J. SandsM. Reck
Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi